HitGen
Chengdu, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A leader in DNA-encoded library and AI-driven small molecule discovery for partnership with global pharma.
OncologyImmunologyInfectious Diseases
Technology Platform
Integrated platform combining massive DNA-encoded compound libraries with AI and machine learning for accelerated small molecule hit discovery and optimization.
Opportunities
Continued expansion of its partnership network and potential for significant milestone payments as partnered programs advance clinically.
Risk Factors
Revenue dependency on partnership fees and milestones, and the risk of technological obsolescence if newer discovery paradigms emerge.
Competitive Landscape
A leading player in the outsourced drug discovery platform space, competing on library size, technology integration, and a strong partnership track record.